Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
For the Phase 1 Portion: To identify the maximum tolerated dose of elotuzumab given in combination with lenalidomide and dexamethasone in subjects with relapsed multiple myeloma. For the Phase 2 Portion: To evaluate the efficacy of elotuzumab given in combination with lenalidomide and dexamethasone in subjects with multiple myeloma after 1 to 3 prior therapies.
Critère d'inclusion
- Patients with relapsed multiple myeloma (MM)